{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-25-000024","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.780311+00:00","generated_at":"2026-05-27T01:44:54.494887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunovant reports Q3 net loss $111.1M; cash $374.7M plus $450M placement","bullets":["Net loss $111.1M ($0.76/sh) vs $51.4M ($0.36) y/y; R&D spend $94.5M up from $48.3M on IMVT-1402 prep.","Pro forma cash ~$825M after $450M private placement closed Jan 15, 2025.","Batoclimab MG pivotal and CIDP period 1 results expected by March 31, 2025.","IMVT-1402: 6 INDs cleared; pivotal GD and D2T RA studies enrolling with autoinjector.","Batoclimab GD additional data (6-month remission) summer 2025; TED top-line H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-25-000024","json":"https://secwatch.observer/filing/0001764013-25-000024.json","markdown":"https://secwatch.observer/filing/0001764013-25-000024.md","text":"https://secwatch.observer/filing/0001764013-25-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/0001764013-25-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/imvt-20250206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:44:54.494887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}